ASTCT/EBMT 6th International Conference on Relapse After Transplant and Cellular Therapy (HSCT²)

Universal City, CA US
November 10, 2023 to November 11, 2023
Hematopoietic stem cell transplantation (HSCT) and cellular therapy are life-saving treatment options for many hematologic malignancies and some solid tumors. Relapse and disease progression are the leading causes of treatment failure for most hematologic malignancies both allogeneic and autologous HSCT. During the last five years, significant advances have been made in the understanding of the biology of relapse, including understanding the role of human leukocyte antigens (HLA) loss, clonal evolution, and T-cell exhaustion. Experts agree healthcare professionals must stay current on research and changes in this field. Remaining informed on best practices, the latest treatment options, preventive strategies, and management of toxicities in relapse after HSCT and cellular therapy will aid healthcare teams and researchers in improving patient outcomes.

This activity will provide a forum for participants to learn about and discuss the latest developments and therapeutic approaches for preventing and treating relapse after HSCT and cellular therapy. It will include presentations, panel discussions, and Q&A on gaps in knowledge, current research, and topics for future study relative to the biology, natural history, prevention, and treatment of relapse following allogeneic HSCT and cellular therapy.

Target Audience

This activity is designed for hematologists and oncologists, hematopoietic stem and immune cell translational and basic scientists, hematopathologists, physicians-in-training, advanced practice providers, pharmacists, oncology nurses, and other healthcare professionals dedicated to providing the highest level of care in HSCT and cellular therapy for hematologic malignancies.

Learning Objectives

After this activity, participants will be able to:

  • State the basic mechanisms of relapse after transplant and cellular therapies;
  • Recognize risk factors for relapse after transplant and cellular therapies;
  • Recognize the importance of clinical trials in this patient population;
  • Identify strategies to prevent relapse after transplant and cellular therapies;
  • Identify treatment strategies that can be used to treat patients who have relapsed after transplant.
Additional information
ACGME/ABMS Core Competencies: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
For more information, please contact:
CME Coordinator Contact Name: 
Anna Hawkshead
CME Coordinator Contact Email: 
CME Coordinator Contact Phone: 
Available credit: 
  • 12.25 AMA PRA Category 1 Credit™
  • 12.25 Participation
Event starts: 
11/10/2023 - 8:00am
Event ends: 
11/11/2023 - 3:30pm
Activity opens: 
Activity expires: 

Day 1: Friday, November 10

8:00 - 8:05 a.m.
Welcome and Introduction
Alan Wayne, MD; Children's Hospital Los Angeles/University of Southern California
Michael Bishop, MD; University of Chicago
Sergio Giralt, MD; Memorial Sloan Kettering Cancer Center
Nicolaus Kroger, MD; University Hospital Hamburg
8:05 - 8:15 a.m.
Message from the ASTCT and EBMT Presidents
Miguel Perales, MD; Memorial Sloan Kettering Cancer Center
Anna Sureda, MD; Institut Català d'Oncologia-Hospital Duran i Reynals
8:15 - 9:00 a.m.Keynote: Immunometabolic control of immunity and the effects of fever
Jeffrey C. Rathmell, PhD; Vanderbilt University
9:00 - 10:30 a.m.
Session I.A: Immune Reconstitution 
Session Chairs: Katharine Hsu, MD, PhD; Memorial Sloan Kettering Cancer Center; Marcel van den Brink, MD, PhD; Memorial Sloan Kettering Cancer Center
  • Title: NK-like T cells: broad Broad Immunityotential for cell therapy 
  • Speaker: Katharine Hsu, MD, PhD; Memorial Sloan Kettering Cancer Center
  • Title: Harnessing mechanisms of tissue regeneration to boost T cell reconstitution after HCT
  • Speaker: Jarrod Dudakov, PhD; Fred Hutchinson Cancer Center
Session I.B: Microbiome
Session Chairs: Katharine Hsu, MD, PhD; Memorial Sloan Kettering Cancer Center; Marcel van den Brink, MD, PhD; Memorial Sloan Kettering Cancer Center
  • Title: Microbiome, HCT, and Immunotherapy
  • Speaker: Jonathan Peled, MD, PhD; Memorial Sloan Kettering Cancer Center
  • Title: Microbial metabolites rescue antibiotic-associated neutropenia
  • Speaker: Katherine King, MD, PhD; Baylor College of Medicine 
10:30 - 11:00 a.m.
11:00 - 11:45 a.m.
Session II: Mechanism of Relapse – Allo
Session Chairs: Leslie Kean, MD, PhD; Dana-Farber Cancer Institute/Boston’s Children Hospital; Luca Vago, MD, PhD; San Raffaele Scientific Institute
  • Title: Leukemia Immune Escape and Relapse after Allogeneic HCT: From Biology to Personalized Medicine (And Back)
  • Speaker: Luca Vago, MD, PhD; San Raffaele Scientific Institute
  • Title: Depletion of exhausted alloreactive T cells enables targeting of stem-like memory T cells to limit relapse after HSCT
  • Speaker: Simone Minnie, PhD; Fred Hutchinson Cancer Center
11:45 - 1:00 p.m.

12:00 - 12:45 p.m.

Pfizer Product Theater

1:00 - 1:45 p.m.

Session III: Mechanism of Relapse – Auto
Session Chairs: Anna Sureda, MD; Institut Català d'Oncologia-Hospital Duran i Reynals; Marcos de Lima, MD; Ohio State University

  • Title: Mechanisms of relapse after ASCT in multiple myeloma

  • Speaker: Niccolo Bolli, MD, PhD; Universita degli Studi di Milano Statale

  • Title: Lymphoma recurrence after autologous stem cell transplantation

  • Speaker: Lapo Alinari, MD, PhD; Ohio State University

1:45 - 2:15 p.m.


2:15 - 3:30 p.m.

Session IV: Mechanism of Relapse – CAR Resistance 

Session Chairs: Nirali Shah, MD, MHSc, National Cancer Institute; Michael Bishop, MD; University of Chicago 

  • Title: Determinants of resistance to anti-CD19 CAR T-cells in large B-cell lymphoma

  • Speaker: Brian Sworder, MD, PhD; Stanford Health Care

  • Title: Harnessing CAR/TCR cross-talk to enhance immunotherapeutic precision

  • Speaker: Naomi Taylor, MD, PhD; National Cancer Institute

  • Title: ALL relapse prevention with HCT following CD19 CAR T cell remission

  • Speaker: Corrine Summers, MD; Seattle Children's Hospital/Fred Hutchinson Cancer Center

3:30 - 4:15 p.m.
Keynote Lecture: Towards the Development of Synthetic Immunity to Cancer

Kole Roybal, PhD; University of California, San Francisco
4:15 - 5:15 p.m.
Best Oral Abstracts
  • Abstract Title:  Guided Lymphocyte Immunopeptide Derived Expansion(GLIDE) and Infusion, a Phase I clinical trial of anti-minor histocompatibility antigen expanded T cells to target leukemia relapsing after HLA-matched Allogeneic Hematopoietic Stem Cell Transplantation
  • Abstract Presenter: Sylvie Lachance MD, FRCPC; Hôpital Maisonneuve-Rosemont
  • Abstract Title: Trem-cel, a CRISPR/Cas9 gene-edited allograft lacking CD33, shows rapid primary engraftment with CD33-negative hematopoiesis in patients with high-risk AML and avoids hematopoietic toxicity during gemtuzumab ozogamicin (GO) post-hematopoietic cell transplant (HCT) maintenance
  • Abstract Presenter: Guenther Koehne, MD, PhD; Miami Cancer Institute 
  • Abstract Title: Immune reconstitution in human bone marrow demonstrates unique features that may correlate with leukemia relapse risk post-transplant
  • Abstract Presenter: Susan Ehrenkranz De Wolf, MD; Memorial Sloan Kettering Cancer Center
  • Abstract Title: Mutation clearance of driver mutations after transpTransplantationyelofibrosis predicts outcome
  • Abstract Presenter: Nico Gagelmann, MD; University Medical Center Hamburg-Eppendorf 
    5:15 - 6:45 p.m.
    Welcome Reception 


    Day 2: Saturday, November 11

    7:00 - 8:00 a.m.
    Product Theater
    8:00 - 8:45 a.m.
    Keynote Lecture: Missing the Major Correlate of Risk of Posttransplant Relapse

    John DiPersio, MD, PhD; Washington University, St. Louis
    8:45 - 9:30 a.m.
    Session V: Mechanism of Relapse - Focus on T Cells 
    Session Chairs: Robert Zeiser, MD; University of Freiburg; Shannon McCurdy, MD; University of Pennsylvania
    • Title: How to improve the anti-tumor activity of T cells – metabolism gives some answers
    • Speaker: Petya Apostolova, MD; University of Basel, Switzerland
    • Title: Lessons from azithromycin after alloHSCT: how an antibiotic can promote relapse by disrupting immune and metabolic networks
    • Speaker: David Michonneau, MD, PhD; Hopital Saint-Louis
    9:30 - 10:00 a.m.
    10:00 - 11:15 a.m.
    Session VI: Minimal Residual Disease
    Session Chairs: Charles Craddock, MD; University Hospitals of Birmingham; Brenda Sandmaier, MD; Fred Hutchinson Cancer Center
    • Title: MRD and Relapse after Transplant in Patients with AML
    • Speaker: Sylvie Freeman, DPhil, MBChB, MRCP, FRCPath, University of Birmingham
    • Title: Using MRD to Predict and Prevent Relapse after HCT and CAR Therapy
    • Speaker: Michael Pulsipher, MD; University of Utah
    • Title: Assessment, considerations, and management of Multiple myeloma patients following front line autologous stem cell transplantation
    • Speaker: Graham Jackson, MD; Newcastle University 
    11:15 - 12:30 p.m.
    Session VII: Relapse Prevention
    Session Chair: David Porter, MD; University of Pennsylvania 
    • Title: Non-targeted strategies for relapse prevention
    • Speaker: Victoria Potter, BSc, MBBS; Kings Private Hospital
    • Title: FLT3 inhibitors as maintenance therapy after HCT
    • Speaker: Alexander Perl, MD; University of Pennsylvania
    • Title: Inhibition of MDM2 for relapse prevention
    • Speaker: Nana Talvard-Balland, PhD; University of Freiburg
    12:30 - 1:45 p.m.

    12:45 - 1:15 p.m.

    Institute for Regenerative Medicine
    1:45 - 3:15 p.m.
    Session VIII: Treatment of Relapse
    Session Chairs: Rayne Rouce, MD;  Texas Children’s Hospital/Baylor College of Medicine;  Saar Gill, MD, PhD; University of Pennsylvania; Bronwen Shaw, MD, PhD; CIBMTR/Medical College of Wisconsin; Takanori Teshima, MD, PhD; Hokkaido University
    • Title: Treatment of Relapse Post Allogeneic Stem Cell Transplantation: A Overview
    • Speaker: Saar Gill, MD, PhD; University of Pennsylvania
    • Title: How I treat AML relapse post allogeneic stem cell transplantation
    • Speaker: Leonido Luznik, MD; Johns Hopkins Medicine
    • Title: Treatment of Relapsed Myeloid Disease Post Allogeneic HCT: HMA, Venetoclax and DLI
    • Speaker: Hugo Fernandez, MD; Moffit Cancer Center
    • Title: 4 How I treat ALL relapse post allogeneic stem cell transplantation(including Ph+ Ph-, and T-ALL)
    • Speaker: Rayne Rouce, MD; Texas Children's Hospital/Baylor College of Medicine 
    3:15 - 3:30 p.m.
    Concluding Remarks

    The agenda is subject to change.

    Sheraton Universal Hotel
    333 Universal Hollywood Drive
    Universal City, CA 91608
    United States
    A block of rooms has been held at the Sheraton Universal Hotel.

    Nestled below the Hollywood Hills, the AAA 4-diamond Sheraton Universal Hotel is just steps away from Universal Studios Hollywood and CityWalk. A short walk to Metro’s red line, easily reach L.A. attractions such as the Walk of Fame, the Hollywood Bowl, and Grauman's Chinese Theatre. Guest rooms pay homage to their Hollywood roots and offer a modern, sleek, minimalist ambiance. Recharge with the Sheraton Signature Sleep Experience®, free Wi-Fi, smart T.V.s, and floor-to-ceiling windows with stunning views of the San Fernando Valley and Hollywood Hills. Enjoy breakfast at The California's, ride our free shuttle to Universal Studios Hollywood theme park; unwind at the pool and seasonal poolside lounge and end your day at In the Mix, our sleek hotel bar serving an extensive selection of beverages. Guests will be dazzled with a 270° view of Hollywood from the 20-foot windows of the rooftop Starview Room.

    Whether it's a business trip or a family vacation, the Sheraton Universal Hotel experience awaits you. Click here to secure your discounted rate!

    Room Rate $279.00 plus 16.19% tax per night (single/double). The room rate will increase by $20 per night for additional persons. 

    Housing Rate Cutoff To take advantage of the discounted room rate, book your reservation on or before October 18, 2023. After October 18, the room block will be released, and the negotiated room rates may not be available. Please make sure the hotel is aware of any special needs. They will assign specific room types and any other requests based on availability.

    Deposits Please have your credit card information on hand upon booking your reservation. The Sheraton Universal Hotel requires each reservation to be guaranteed with a deposit equal to one night's room and tax.

    Changes or Cancellations The Sheraton Universal Hotel requires that you cancel your reservation (72) hours before your arrival. The deposit of one night's room and tax will be forfeited for cancellations made less than (72) hours from arrival. Please call the hotel directly to make a cancellation and keep your cancellation confirmation number for your records. Name changes can be made to reservations before check-in, without incurring a fee.

    Confirmations The hotel will send you a confirmation to the email used in booking your reservation using the customized online reservation link provided by ASTCT-EBMT. Review it carefully for accuracy and keep a copy for your records.

    ACCESSIBILITY The ASTCT and EBMT are committed to providing equal access appropriate to need and circumstances and complies fully with legal requirements of the Americans with Disabilities Act. If you are in need of special accommodation, please contact Anna Hawkshead at 312-673–4965 or via email at

    ASTCT and EBMT reserve the right to cancel or postpone this conference due to unforeseen circumstances. In the unlikely event this activity must be cancelled or postponed, the registration fee will be refunded; however, ASTCT and EBMT are not responsible for any related costs, charges, or expenses to participants, including fees assessed by airline/travel/lodging agencies.
    Michael R. Bishop, MD  Michael Bishop, MD
      Professor of Medicine
      Director, Hematopoietic Stem Cell Transplantation Program
      University of Chicago

    Sergio Giralt, MD  Sergio Giralt, MD
      Deputy Division Head, Division of Hematologic Malignancies
      Melvin Berlin Family Chair in Multiple Myeloma
      Memorial Sloan Kettering Cancer Center


    Nicolaus Kröger, MD  Nicolaus Kröger, MD
      Director, Department of Stem Cell Transplantation
      University Hospital Hamburg


    Alan Wayne, MD  Alan Wayne, MD
      Director, Cancer and Blood Disease Institute
      Head, Division of Hematology-Oncology
      Attending Physician, Hematology-Oncology
      Alfred E. Mann Family Foundation Chair in Cancer Research
      Professor of Pediatrics and Medicine
                             University of Southern California
    Disclosure Declarations
    As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.

    Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
    Physician Credit
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Chicago Pritzker School of Medicine and the American Society for Transplantation and Cellular Therapy. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
    The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 12.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
    Other Participants Credit
    Other participants will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
    Please Note: The credit claiming process will close three months after the conference end date. Requests to claim credit after three months will be subject to additional fees.
    This conference offers a tremendous opportunity to highlight your company's products, services, and achievements in front of a wide array of key decision-makers. Increase your company profile by participating as an exhibitor at this exciting event.
    We are pleased to provide opportunities for organizations to advertise their products and services to conference participants. Whether you are connecting with physicians during scheduled breaks, leading a special sponsored session about your products, or gaining brand recognition for your company through program acknowledgments and other sponsorship opportunities, your message will reach physicians, nurses, and other healthcare professionals.
    Download the prospectus PDF icon here or contact ASTCT at or (312) 673-4833. We hope to see you there!

    Fall in Los Angeles

    Registration: Registration is open, so reserve your space today!

    Profession Type
    Standard Registration (MD, PhD)
    Trainees and Junior Faculty
    Other Healthcare Professionals
    CANCELLATION POLICY Please see the registration site for the full details.


    Claiming Credit: Enter the access code to unlock the credit-claiming process.
    Please Note: The credit claiming process will close three months after the activity ends. Requests for certificates after three months will be subject to additional fees.
    Please login or create an account to proceed.